Ken Bartizal, Chief Development Officer at Trius Therapeutics Inc (TSRX), sold 1,687 shares at $7.85 ($13K) on 2011-11-17, disclosed to the SEC on 2011-11-18.
Scheduled sale ($13k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TSRX | SELL | 2013-05-28 | $94K | — | Filing → |
| TSRX | SELL | 2013-05-28 | $95K | — | Filing → |